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Context: The optimal measure of vitamin D(D) status is unknown. 
Objective: Directly measure circulating free 25(OH)D concentrations and relationships to total 
25(OH)D in a clinically diverse sample of humans. 
Design: Cross-sectional analysis 
Setting:  Seven academic sites 
Patients:  1661 adults: (healthy(n=211), pre-diabetic(n=479), outpatients(n=783), 
cirrhotic(n=90), pregnant(n=20), nursing home(n=79))  
Interventions:  Merge research data on circulating free 25(OH)D (directly measured 
immunoassay), total 25(OH)D (LC/MS/MS), D binding protein (DBP by radial (polyclonal) 
immunodiffusion assay)), albumin, creatinine, iPTH and DBP haplotype 
Main outcome measures: Distribution of free 25(OH)D (ANOVA with Bonferroni correction 
for post hoc comparisons) and relationships between free and total 25(OH)D (mixed effects 
modeling incorporating clinical condition, DBP haplotype with sex, race, eGFR, BMI and other 
covariates).  
Results: Free 25(OH)D was 4.7±1.8 pg/mL (mean ±SD) in healthy and 4.3 ±1.9 pg/mL in 
outpatients with 0.5-8.1 pg/mL and 0.9-8.1 pg/mL encompassing 95% of healthy and outpatients, 
respectively. Free 25(OH)D was higher in cirrhotics (7.1 ±3.0 pg/mL, p<.0033) and nursing 
home residents (7.9± 2.1pg/mL, p<.0033) compared to other groups and differed between whites 
and blacks (p<.0033) and between DBP haplotypes (p<.0001). Mixed effects modeling of 
relationships between free and total 25(OH)D identified clinical conditions (cirrhotic>nursing 
home>prediabetic > outpatient > pregnant), and BMI (lesser effect) as covariates affecting 
relationships but not eGFR, sex, race or DBP haplotype.  
Conclusions:  Total 25(OH)D, health condition, race and DBP haplotype affected free 
25(OH)D, but only health conditions and BMI affected relationships between total and free 
25(OH) D. Clinical importance of free 25(OH)D needs to be established in studies assessing 
outcomes.  
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Free 25(OH) D levels were affected by clinical conditions as well as race, BMI, or DBP haplotype.  
Relationships between free and total 25(OH)D were only affected by clinical conditions and BMI. . 
1. Introduction 
The adequacy of vitamin D status is usually assessed by measurement of total circulating 25(OH) 
vitamin D (25(OH)D) levels. Total circulating 25(OH)D includes 25(OH)D bound to vitamin D 
binding protein (DBP) estimated to be about 85% of total with about 10-15% bound to albumin 
and a very small fraction as free or unbound 25(OH)D. As DBP is the main carrier for 25OHD 
and other vitamin D metabolites, its concentration and affinity are the main drivers of the free 
concentration of 25(OH)D and other D metabolites. If the free hormone hypothesis applies to 
vitamin D biology, only free 25(OH)D is available for conversion to active 1α,25(OH)2 D that 
interacts with the vitamin D receptor regulating hundreds of genes in most cells.  It has been 
shown that health conditions such as cirrhosis that is associated with protein synthetic 
dysfunction resulting in decreased DBP as well as albumin and pregnancy that is associated with 
increased protein synthesis and DBP in the second and third trimesters alter levels of free 
25(OH)D inversely to the changes in DBP. (1-3).  There is uncertainty regarding DBP genetic 
variant effects on free 25(OH)D levels but in vitro DBP affinity constants for 25(OH)D that 
differ between DBP haplotypes would predict altered 25(OH)D binding and differing free 
25(OH)D levels.  (4-7)  Altered albumin concentrations such as the lower levels reported in the 
frail elderly or nursing home residents (8) could also alter free 25(OH)D concentrations, albeit to 
a smaller extent than changes in DBP. Thus, total 25(OH)D may not accurately reflect levels 
available for cellular uptake with the exception of cells in the kidney or parathyroid capable of 
megalin/cubilin-mediated internalization of DBP-bound 25(OH)D.  (9) 
Primary goals of this work were to combine data from human investigations involving direct 
measurement of free 25(OH)D to a) describe the distribution of circulating free 25(OH)D 
concentrations in adult humans with and without various conditions or disease states known to 
alter DBP, with differing DBP haplotypes, with a wide range of body weights as higher BMI 
such as seen in those with obesity, metabolic syndrome or prediabetes has been shown to alter 
total 25(OH)D and calculated free 25(OH)D,(10)  in the very elderly such as nursing home 
patients or women with osteoporosis likely to receive D supplementation or receive exogenous 
female sex hormones in whom free 25(OH)D data are not available;  and, b) to determine 
relationships between free and total 25(OH)D in these clinical conditions and disease states, and 
different DBP haplotypes.  Our findings provide a measure of the normal range of free 25(OH)D 
concentrations as well as new observations on factors that do and do not alter relationships 
between free and total 25(OH)D in clinical populations.   
2. Subjects and Methods 
A. Subjects.   
Investigators who directly measured free 25(OH)D in clinical investigations contributed de-
identified data. Adult groups sampled included: healthy subjects, medically stable community-
dwelling outpatients enrolled in longitudinal or D dosing studies, pre-diabetics, medically stable 
nursing home residents >65 years of age, stable subjects with cirrhosis,  and pregnant women 
(second or third trimester).(2, 11-26) Subjects provided informed consent for research approved 
by the Institutional Review Board of the respective organizations. For investigators, sites, and 
subject description see Appendix.  
B. Laboratory Measurements  
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1. Free 25(OH)D Levels.  Direct measurement of free 25(OH)D concentrations was by immunoassay (Future 
Diagnostics B.V., Wijchen, The Netherlands, http://www.future-diagnostics.nl/) as described. (23) In brief, 
an antibody to 25(OH)D is pre-coated onto a microtiterplate and serum samples and calibrators added.  
Free 25(OH)D is captured during this first incubation step, and after washing, a second incubation with 
biotin-labeled 25(OH)D analog reacts with non-occupied antibody binding sites (competitive 
immunoassay). Finally, after washing and incubating with a streptavidin- peroxidase conjugate, absorbance 
[A450nm] is measured using a plate spectrophotometer, where  concentration of free 25(OH)D in the 
sample is inversely proportional to absorbance in each sample well.  Assay calibration was against a 
symmetric dialysis method. (see http://www.future-diagnostics.nl/) Limit of detection (LOD) for blank 
serum is 0.7 pg/mL;  at 5.02 pg/mL, between-run coefficient of variation (CV) was 6.2% and between-day 
CV was 4.5% with a total imprecision CV of 15.7%. Biotin at 4mg/dL was tested for assay interference and 
mean % interference was 1% at 6.5 pg/mL, 4% at 10.6 pg/mL and 1% at 15.7 pg/mL: free 25(OH)D.  
Assays were performed at Future Diagnostics B.V. except for measurements in pre-diabetics performed in 
Tromso using the Future Diagnostics B.V. kit with the same technique calibrated over the range of 0.1-35 
pg/mL with LOD of 2.8 pg/mL, with inter- and intra-assay CVs <10%. (25) 
2. Total 25(OH)D was determined by liquid chromatography tandem mass spectrometry (LC MS/MS) using 
National Institute of Standards and Technology (NIST) reference standard (U.S. sites participated in 
National Institutes of Health Office of Dietary Supplements funded  quality assurance program for analysis 
of D metabolites in human serum; European sites participated in the external quality program DEQAS with 
the exception that two-thirds of samples from cirrhotics were by immunoassay (Diasorin (LIAISON), and 
the results  converted to (LC MS/MS) equivalent by the manufacturer provided calibration factor.  
3. DBP was measured by radial immunodiffusion (polyclonal) assay (KU Leuven, Belgium) for all groups 
except pregnant (monoclonal ELISA R&D Systems (Minneapolis, MN)). 
4. Albumin, creatinine, calcium, were measured with autoanalysers in clinical laboratories. iPTH was 
measured by multiple immunoassays:  two-site sandwich immunoassay using direct chemiluminometric 
technology (ADVIA Centaur, Siemens, Malvern, PA, for UCSF samples), Diasorin immunoradiometric 
assay (for Creighton University samples), automated clinical chemistry analyzer (Immulite 2000, Siemens 
Healthcare Diagnostics, Los Angeles, CA, USA for Tromso Norway and UK samples), and by 
Scantibodies immunoradiometric assay (Santee, CA) for MrOs samples.  Assay method was coded. 
5. DBP haplotyping (959 subjects). In 471 prediabetics from University of Tromso haplotyping was done by 
KBioscience (http://www.kbioscience.co.uk) using the KBioscience Competitive Allele-specific PCR 
genotyping system; in 205 young and older men and women from Sheffield England at Sheffield 
Children’s Hospital, United Kingdom a pyrosequencing assay was developed with PSQ software (version 
1.0.6; Qiagen) to detect rs4588 and rs7041 polymorphisms;  in 254 older community outpatient men 
(multiple U.S.  MrOS sites), two nonsynonymous GC single nucleotide polymorphisms were used to define 
GC haplotypes, rs4588 (Thr436Lys) and rs7041 (Asp432Glu), and in 29 young normals (MRC/Gambia) 
samples were analyzed at Vesalius Research Center (Katholieke Universiteit, Leuven, Belgium) by iPLEX 
technology on a MassARRAY compact analyzer (Sequenom Inc).  
C. Data analysis.  
Demographic, clinical characteristics, and assay results are presented as mean ± S. D. Analysis 
of variance for trends followed by post hoc analyses for between group comparisons using 
Bonferroni correction for multiple comparisons was used to test for differences in total, free, or 
per cent free 25(OH)D between clinical groups, DBP haplotypes or self-reported racial groups.  
Relationships between free and total 25(OH)D were examined using a mixed effects model 
incorporating clinical condition, DBP haplotypes with sex, race, eGFR, BMI and other 
biologically plausible covariates and interactions.  Relationships between free or total 25(OH)D 
and iPTH were examined in the same manner including iPTH assay method as a covariate. 
Analyses were performed in R (R Core Team (2016). R: A language and environment for 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-
07-0, URL http://www.R-project.org/) using the function lmer from the package lme4).   The 
fixed effect part of the model takes the form Free = a + (b +c COV)Total, where a is the 
intercept, b is the slope of the relationship Free vs Total, and c is a vector of parameters 
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quantifying the relationship of the slope with covariates. Slopes are assumed to be normally 
distributed across individuals. Model selection was conducted using standard procedures 
according to the Akaike Criterion (27) and visual inspection of diagnostic plots. After model 
selection, comparisons to the reference group were computed according to 2-sided t-test using 
the Satterthwaite approximation (R lmerTest). Exploratory analyses of effects of sex hormones 
in women were performed using linear regression.  
3. RESULTS 
A. Subject data.   
Data were from 1661 subjects. Demographic characteristics by clinical group (normal, pre-
diabetic, community-dwelling outpatient, cirrhotic, pregnant, nursing home (NH)) estimated 
glomerular filtration rate (eGFR), albumin, calcium, albumin-corrected calcium, DBP, total and 
free 25(OH)D, and iPTH are in Table 1. 25(OH)D2 was identified in no pregnant, 10% of 
nursing home residents, 25% of cirrhotics, and 61% of normals and outpatients). Average 
25(OH)D2 was < 7% of total in normals and outpatients and 24% of total in cirrhotics. No 
relationship was detected between free 25(OH)D and 25(OH)D2. Assays measuring C3-epimer 
of 25(OH)D were used in 498 samples and C3-epimer was detected in 296 (59%).  C3-epimer 
concentrations over 1 ng/mL were not detected until total 25(OH)D exceeded 20 ng/mL; C3-
epimer was < 2 ng/mL at total 25(OH)D up to 30 ng/mL.   
B. Free 25(OH)D Distribution.  
Distribution of free 25(OH)D concentrations by clinical group is shown in Figure 1. Data 
reflected steady-state conditions with and without D supplementation as part of clinical care (but 
not during dose titration studies). Free 25(OH)D levels from 0.5 to 8.1 pg/mL include 95% of 
healthy subjects and is similar to the 0.9- 8.1 pg/mL range encompassing 95% of the almost three 
times larger group of stable outpatients. Significant effects of clinical condition on free 
25(OH)D, DBP, total 25(OH)D, and per cent free 25(OH)D were detected (ANOVA p<.0001; 
Table 1).  The highest mean free 25(OH)D was in NH residents accompanied by higher total 
25(OH)D and lower DBP than normals, outpatients, prediabetics and pregnant women, but 
higher DBP than in cirrhotics (p<.0033).  The next highest mean free 25(OH)D was in cirrhotics 
(higher than healthy, pregnant, prediabetic, and outpatients (post hoc p<.0033 for all).   Between 
group differences were detected for all comparisons (post hoc p<.0033)  except normals vs. 
pregnant or outpatients, and for pregnant vs. outpatients. Both DBP and total 25(OH)D were 
lowest in cirrhotics. Pregnant women had the second highest total 25(OH)D levels and the 
highest DBP (post hoc p<.0033), despite measurement by a less sensitive assay. Albumin 
concentrations were not correlated with DBP (r2= 0.0004, p=0.83) in the absence of pregnancy or 
cirrhosis. Per cent free 25(OH)D was higher in cirrhotics and nursing home residents compared 
to other clinical groups (post hoc p<.0033) and between group comparisons were significant for 
all but normals compared to pregnant or outpatients, and for pregnant vs. outpatients.   
C. Effects of race and DBP haplotype.  
Genotype data were available for 959 (outpatients, prediabetics and normals, Table 2). Ninety-
eight were of self-reported black race, 860 white and 1 of self-reported other race.  Differences in 
free 25(OH)D between whites and blacks were detected (4.9 ± 1.9 vs. 4.0 ±1.5 pg/mL, 
respectively, p<.0033). As expected, the 1f allele was more common in blacks and the 1s allele 
more common in whites. (Table 2).   Gc 2/2 haplotype was present in 5.5% of whites and no 
blacks. DBP haplotype had significant effects on total 25(OH)D, free 25(OH)D, and DBP 
(ANOVA, p<.0001). The lowest total and free 25(OH)D were seen with the least frequent Gc 2/2 
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haplotype (4.2 ±2.2 pg/mL). Total and free 25(OH)D were higher in the presence of 1s alleles. 
Post hoc analyses detected lower free 25(OH)D levels in 2/2 haplotype compared to 1s/1s or 
1s/1f haplotypes and in 1f/1f haplotypes compared to 1f/1s haplotypes (p<.0033). DBP 
haplotype also affected percent free 25(OH)D (p<.0001) (Figure 2). The lowest percent free was 
seen with the 1s/1s haplotype that was lower compared to 1s/1f, 1f/2, 1f/1f or 1s/2 haplotypes 
(p<.0033). Percent free was higher with 1f/1f haplotype compared to 1s/2, and 1f/2 and was 
higher with 1f/2 compared to the 1s/2 haplotype (p<.0033).  Magnitude of differences, however, 
were less than observed between some clinical conditions.  DBP haplotypes differed in DBP 
concentrations with the 2/2 haplotype having the lowest DBP, total, and free 25(OH)D (post hoc 
p<.0033) yet percent free 25(OH)D that was in the middle of observed means. The highest DBP 
was seen with the 1s/1s haplotype that had the highest total and free 25(OH)D but lowest percent 
free 25(OH)D.  DBP levels were higher for the 1s/1s haplotype compared to any haplotype with 
at least one Gc2 allele (p<.0033) but not when compared to haplotypes 1s/1f or1f/1f.   DBP 
levels were significantly lower for haplotype 2/2 compared to 1f/2,1f/1f; and 1s/1f (p<.0033). No 
differences were detected between haplotypes 1s/1s vs 1s/1f or 1f/1f; 1s/2 vs 1f/2; 1s/2 vs 1f/1f; 
or 1s/1f vs 1f/1f. Differences between haplotypes 1s/1f vs 1f/2 approached (p=.0045) but failed 
to reach p<.0033 post hoc criteria for significance). 
D. Relationships between free and total 25(OH)D.  
Individual data are plotted by clinical group and DBP haplotype in Figure 3. Linear mixed 
effects modelling identified significant contributors to the relationship as the clinical condition 
and BMI. (see Table 3).  Rejected covariates included eGFR and race.  Clinically normal 
subjects are associated with the baseline slope (b) of the model.  The steepest slope (b+0.1577) 
was in cirrhotics with the lowest DBP, the second steepest slope was in NH subjects with the 
second lowest DBP levels, and the least steep slope was in pregnant women with the highest 
DBP.  Excluding cirrhosis and pregnancy from the model, sex was selected for inclusion (male 
sex with coefficient estimate of 0.03 ±.004).  DBP haplotype effects on the free vs. total 
25(OH)D relationship were not detected in subjects (n=959) with these data. 
E. Relationships between free and total 25(OH)D and iPTH.   
Both total and free 25(OH)D concentrations were negatively related to iPTH levels, but the 
mixed effects model fits favored total 25(OH)D (coefficient estimate of -0.96 ±0.51). Covariates 
selected included BMI (continuous variable) with a small effect (0.02±.004) and iPTH assay 
method that varied within the sites precluding further clinical group analyses.  
F. Exploratory analyses-  female sex hormones.  
Forty young non-pregnant and non-cirrhotic women reported taking oral contraceptives (OC). 
Total and free 25(OH)D were 21.0 ± 13.1 ng/mL and 3.4±2.2 pg/mL, respectively, not different 
from total or free 25(OH)D levels of 20.1±8.3 ng/mL and 3.6±1.5 pg/mL in 21 young non-
pregnant non-cirrhotic women not taking oral contraceptives.   Relationships between free and 
total 25(OH)D in oral contraceptive users had a slope of 0.150 (lower 95% confidence interval 
(C.I.)  of 0.126 and upper 95% C.I. of 0.175) compared to slope of 0.125 (lower 95% C.I. of 
0.066 and upper 95% C.I. of 0.185) in non-users (ns). Thirty-five postmenopausal women 
reported estrogen use for hormone replacement, and 82 age-health matched women reported no 
use. Total 25(OH)D concentrations were 24.8 ±11ng/mL in estrogen users vs. 26.1 ±10.2 in non-
users.  Free 25(OH)D was 4.4±2 in estrogen users and 4.6±2.2 pg/mL in non-users (ns), and the 
slope of relationships between free and total 25(OH)D did not differ (users:  0.164 (lower 95% 
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CI of 0.136 and upper 95% C.I.  of 0.195 compared to slope of 0.158, lower 95% C.I. of 0.124 
and upper 95% C.I. of 0.192 in non-users). DBP data were not available. 
4. DISCUSSION 
There is currently debate about the best serum measurement to determine vitamin D status. (4) 
Circulating levels of 25-hydroxyvitamin D (25(OH)D) are the most commonly used marker 
because its concentration in blood is higher than other D metabolites making it easier to measure, 
its conversion from vitamin D is substrate dependent with minimal regulation, and it has a 
relatively long circulating half-life. However, the free hormone hypothesis postulates that only 
non-bound or “free” fraction of hormones that circulates in blood can enter cells and exert 
biologic effects.  This would suggest that the free fraction is key to the intracrine functions of 
vitamin D except in cells such as those in the kidney or parathyroid gland capable of 
megalin/cubilin-mediated internalization of DBP-bound 25(OH)D. (9) 
Assays to directly measure free 25(OH)D are not currently applied in clinical care but have 
been utilized in research investigations.  It has been demonstrated that directly measured free 
25(OH)D concentrations differ from estimated (calculated) free 25(OH)D concentrations based 
on DBP assays using monoclonal or polyclonal antibodies and single or DBP haplotype 
estimated DBP dissociation constants. (2, 3, 6, 19, 21-23, 28) Directly measured free 25(OH)D 
has also been reported to correlate better than total 25(OH)D with some biologic measurements 
(2, 3, 6, 19, 21-23, 28), whereas other reports do not report a stronger relationship (summarized 
in (4-7)).  Most investigations, however, have small sample sizes or selected populations such 
that the distribution of free 25(OH)D concentrations in many clinical populations is unknown.  
This paper is the compilation of data from an international Working Group of Vitamin D 
investigators in order to describe free 25(OH)D concentrations in a wide range of people with 
various clinical conditions.  The data were from healthy young and older people, people with 
pre-diabetes, community-dwelling outpatients enrolled in longitudinal studies or vitamin D 
studies, pre- and post-menopausal women with low vitamin D status, pregnant women, 
cirrhotics, and nursing home residents with multiple morbidities enrolled in observational or 
vitamin D studies. A major strength is that our international data represent by far the largest and 
most diverse sample of adults studied to date and included patients with conditions that alter both 
free 25(OH)D levels and the relationship between free and total 25(OH)D, groups for whom 
these data have not been previously available. Importantly, 98% of DBP measures were 
performed with one polyclonal method at one laboratory, and 95.8% of 25(OH)D measures were 
performed by labs participating in quality standardization programs (National Institute of 
Standards and Technology (NIST)  or Vitamin D External Quality Assessment Scheme 
(DEQAS)) and 100% of free 25(OH)D measurements were performed using the same method. 
A strict definition of “normal” subjects was used to identify people with normal laboratory 
chemistry tests, no known chronic medical diseases, and no chronic oral medications excepting   
thyroid, hormone replacement therapy, oral contraceptives or dietary supplements. In these 
individuals, the mean concentration of free 25(OH)D was 4.3±1.9 pg/mL when mean total 
25(OH)D concentration was 21.9 ±9.9 ng/mL.  A range from 0.5 to 8.1 pg/mL included 95% of 
healthy normal subjects and was similar to the 0.9- 8.1 pg/mL range encompassing 95% of the 
nearly three times larger group of stable outpatients.  Mean free and total 25(OH)D 
concentrations as well as percent free were slightly higher in prediabetics yet the upper bound of 
the 95% confidence interval was similar at 8.9 pg/mL.  Free 25(OH)D measurements in pre-
diabetics was performed using the same technique but at a different site than all other assays and 
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some assay variation may explain the small differences (as some diabetics were included in the 
outpatient samples and did not show either higher free or percent free 25(OH)D (data not 
shown). In our prior observations in pregnant women and a subset of the cirrhotics, DBP was 
measured using a monoclonal antibody DBP assay. (1-3, 23) In the current analyses a polyclonal 
antibody was used in the radial immunodiffusion assay performed at the same laboratory for all 
groups with the exception of the pregnant women. The data on the current larger group of 
cirrhotics are consistent with early reports of lower DBP with higher directly measured mean 
free 25(OH)D  despite lower total 25 (OH)D levels. (26) The data from pregnant women mirror 
the almost two-fold higher DBP initially reported in pregnant women in the second and third 
trimester compared to non-pregnant women (29, 30) and with less variability in free 25(OH)D. 
Although the group of pregnant women was small, similar mean free 25(OH)D with lesser 
variability than in other groups has been reproduced using the same methods in a larger group of 
about 300 Caucasian women, despite somewhat higher DBP in the second and third trimesters 
when measured by ELISA with a polyclonal antibody.(31) We had limited data on women 
reporting oral contraceptive use or hormone replacement therapy with estrogen, but free 
25(OH)D levels and relationships between total and free 25(OH)D did not appear to be 
significantly influenced by use of these agents at currently prescribed dosages and routes of 
administration.  
An unexpected observation was that mean free 25(OH)D was higher in the nursing home 
residents with distribution of values shifted toward higher concentrations.  Likely contributors 
were both the lower DBP levels and the higher total 25(OH)D in the nursing home residents 
compared to the normal subjects, prediabetics, community-dwelling and pregnant subjects.  
Mean albumin concentrations were slightly lower in the nursing home residents compared to 
normals, outpatients, or prediabietcs but as only 12-15% of 25(OH)D is bound to albumin it is 
unlikely to have been a major factor. Inflammation and/or elevated cytokines that accompany 
very old age (32) or multiple morbidities could also alter affinity of 25(OH)D to DBP. Whatever 
the underlying mechanisms, both percent free 25(OH)D concentrations and the relationship 
between free and total 25(OH)D differ in pregnant women, people with cirrhosis, and elderly 
people with multiple morbidities compared to normals or community-dwelling outpatients, and 
relationships are affected to a much smaller extent by BMI in all groups.  It also appears that 
stable medical conditions such as hypertension, prediabetes, diabetes, osteoporosis, or mild renal 
disease do not appear to significantly alter relationships between free and total 25(OH)D.   
Free 25(OH)D concentrations are related to total 25(OH)D concentrations as well as albumin 
and DBP and their binding affinities for 25(OH)D.  (29) DBP is a highly polymorphic protein. 
(33) Our sample included whites and blacks and several Asians, and distribution of DBP 
haplotypes mirrored reported racial differences in that black (and Chinese) populations are more 
likely to carry the Gc1f allele and whites more likely to possess the Gc1s and the less frequent 
Gc2 allele. (34) DBP haplotype affected DBP and both total and free 25(OH)D concentrations. 
The Gc2/2 haplotypes and presence of 1f alleles  were associated with lower total 25(OH)D 
concentrations as previously reported.  (35)   Gc1f has been reported to have the highest affinity 
and Gc2 the lowest affinity for vitamin D and its metabolites, but this has not been uniformly 
detected. (7, 33, 36, 37) In our sample, the highest percent free was seen with the 1f/1f haplotype 
and 1f/2 haplotypes and the lowest percent free was seen with 1s/1s despite similar DBP 
concentrations. Mean percent free 25(OH)D in people with the 2/2 haplotype was in the 
midpoint of the range and did not differ significantly from the 1s/1f or 1s/ 2 haplotypes.  These 
data do not support the earlier report of Gc1f having the highest and Gc2 having the lowest 
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affinity for 25(OH)D. The maximum mean percent differences between haplotypes was on the 
order of about 19-24 percent. DBP concentrations differed between some haplotypes, and free 
25(OH)D concentrations were in the expected relationship—i.e. higher free 25(OH)D 
concentrations with lower DBP, but the percent free 25(OH)D did not show the same 
relationship.  In contrast to differences in percent free 25(OH)D by DBP haplotype, haplotype 
was not selected as a significant covariate in the linear mixed effects model of relationships 
between free and total 25(OH)D in these individuals.  This suggests that haplotype does not have 
a marked effect on the relationship.  We did not have DBP haplotype data on cirrhotics, nursing 
home residents or pregnant women to allow comparisons of clinical condition effects to 
haplotype effects in the same model. Nevertheless, the magnitude of differences seen between 
the clinical groups was greater than that seen between DBP haplotypes.  
This study has limitations.  Data were not from random population-wide samples and 
analyses of BMI, sex, race or other subgroup effects might not be representative of all 
populations.  Samples were from medically stable individuals and may not apply to acute 
medical conditions. The only potential biomarker for vitamin D status analyzed was iPTH with 
differing methods in clinical laboratories limiting our analyses. However, the parathyroid gland 
has the megalin/cubilin mechanism for cellular uptake of DBP, so PTH levels are unlikely to 
discriminate between free and total 25(OH)D effects on biological function.  Bone biomarkers 
were not assessed. Bone density has been reported to correlate better with measures of free than 
total 25(OH)D in the prediabetics included in the current analyses (19),  but others have found 
similar relations between markers of bone metabolism and free or total 25(OH)D. (38) However,  
D and bone relationships are somewhat difficult to interpret as measures of vitamin D and its 
metabolites are often done only at a single timepoint while bone density is the result of 
cumulative time effects. As many of the subjects sampled received D supplementation, we could 
not address seasonal effects.  
5. CONCLUSIONS.  
Free 25(OH)D concentrations are affected by health conditions in addition to total 25(OH)D 
concentrations and DBP haplotype. Free 25(OH)D distributions were similar in normal 
individuals and stable community-dwelling outpatients with 95% within the range of 0.5 to 8.1 
pg/mL and 0.9- 8.1 pg/mL, respectively.  Per cent free 25(OH)D was affected by clinical 
condition (cirrhotics>nursing home residents, >outpatient, >normal>pregnant), self-reported race 
(black>white>Asian), and DBP haplotype (1f/1f +1f/2>1f/1s,2/2, 1s/2>1s/1s).  Relationships 
between free and total 25(OH)D were influenced by BMI to a small extent and to a larger extent 
by health conditions with cirrhotics and nursing home residents having the steepest slopes and 
pregnant women the least steep without significant effects of DBP haplotype detected in mixed 
effects models. Clinical outcomes data other than PTH levels are needed to determine the role of 
free 25(OH)D measurements in clinical decision-making with the growing recognition of the role 
that vitamin D and its metabolites play in promoting optimal health beyond bone and calcium 
absorption metabolism. (39) Currently, most vitamin D intake recommendations are based on 
immunoassay-measured  total 25(OH)D levels associated with lower risk of  osteoporotic 
fractures in postmenopausal women.  (40) Clinicaltrials.gov lists over 600 completed phase 2, 3, 
and 4 trials of vitamin D relationships to various health conditions, 59 active and not recruiting, 
149 clinical trials currently recruiting and 36 in the planning stages. (https:\\clinical trials.gov 
accessed May 30, 2018). Results from two very large randomized double-blind trials 
investigating vitamin D supplementation effects on cancer, cardiovascular disease and mortality 
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(VITAL:NCT01169259, and VIDAL:ISRCTN46328341) will soon be available and will provide 
data on relationships with total 25(OH)D.    However, to the extent that the free hormone 
hypothesis applies to cellular availability of vitamin D metabolites, total 25(OH)D measurements 
may be misleading in subjects with altered total to free relationships and analysis of free 
25(OH)D could provide further insights.  
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Figure 1.  Distribution of free 25(OH)D concentrations are shown for Normal subjects, stable 
community-dwelling Outpatients, Pregnant women, elderly Nursing Home residents, and 
Cirrhotics. Free 25(OH)D concentrations are on the horizontal axis, and the number of subjects is 
plotted on the vertical axis.  The curved line represents the normal distribution. Data are only 
study entry (baseline) concentrations for any subjects enrolled in vitamin D supplementation or 
dose titration studies. 
Figure 2.  Per cent free 25(OH)D concentrations are presented by Clinical Subgroup in the left 
panel and by DBP haplotypes in the right panel (subset of n=974).   The box plot shows the 10th, 
25th, median, 75th and 90th percentile values.  Individual points represent values above the 90th 
and below the 10th percentile. Both clinical subgroup and DBP genotype had significant effects 
on per cent free 25(OH)D (ANOVA, p<.0001). *Horizontal parentheses indicate statistically 
significant post hoc between group comparisons (meeting Bonferroni criteria of p<.0033).  Post 
hoc between clinical group comparisons were significant for all but normals compared to 
pregnant or outpatients, or for pregnant compared to outpatients.  For DBP haplotypes, smaller 
but significant differences were detected between the 1s/1s haplotype and 1s/1f, 1f/2, 1f/1f, and 
1s/2 haplotypes; and between the 1s/2 and 1f/2 and 1f/1f haplotypes and between the 1s/1f and 
1f/1f haplotypes. 
Figure 3. Relationships between free and total 25(OH)D by clinical subgroup and DBP 
haplotype.  Total 25(OH)D concentration is plotted on the x axis and free 25(OH)D 
concentration is plotted on the y axis.  In the left panel, open circles represent data from 
community-dwelling outpatients, closed blue circles represent data from older nursing home 
(NH) residents, closed brown circles represent data from cirrhotics, pink x represent data from 
pregnant women, half- filled circles represent data from prediabetics, and closed green circles 
indicate data from normal/healthy subjects. Data include multiple measures in a subset of healthy 
normal and NH residents enrolled in vitamin D supplementation studies (n=243 samples). In the 
right panel, closed blue circles represent the 1s/1s DBP haplotype, half blue and half white 
circles represent 1s/2 haplotypes, solid green circles represent 1s/1f, solid diamonds represent 
2/2, open cross hatched diamonds represent 1f/2, and solid red circles represent 1f/1f.  DBP 
haplotype data were from normals, community-dwelling outpatients, and prediabetics. Linear 
mixed modelling detected significant effects of clinical groupings on the relationship between 
free and total 25(OH) D (*p<.05, **  p<.0001, ***  p<.000001 for comparisons to 
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normal/healthy subjects).  Significant effects of DBP haplotype on the relationship were not 
detected.  
Table 1. Description of Populations Sampled and Serum Measurements by Clinical Subgroups  
 Normal Community-
dwelling Outpatients 
Prediabetics Cirrhotics Nursing 
Home 
Pregnant 
N (%) 279 (16.8) 714 (43) 479 (28.8) 90 (5.4) 79 (4.8) 20 (1.2) 
Age 36.6±8.5 68.7±8.5 62±8.6 58.0±8.8 87.4± 8.0 30.7±6.9 
Sex –Women n (%) 178 (63.8) 324 (45.4) 184 (38.4) 36 (40) 51 (64.6) 20 (100) 
         Men  90 (32.3) 390 54.6) 295 (61.6) 54 (60) 28 (35.4) 0 (0) 
          unknown 11 (3.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Race- White, black 187, 65 (67, 23.3) 518,191 (72.5, 26.8) 479, 0 (100,0) 69, 11 
(76.7,12.2) 
78, 0 (98.7) 15, 4 (75, 20) 
 Asian, other, Nat 
Amer, unknown 
  12, 1, 2, 12 
(4.3,0.4,7.2,4.3) 
3, 0,2, 0 0.4,0,0.3,0) 0,0,0,0 6, 0, 4 (6.7, 
0,4.4) 
1 (1.3) 1 (5) 
Weight (kg) 78.5±18.6 83.7±16.7 88.4±16.6 85.5 ± 18.8 69.9 ± 16.4 81.1  ±20.9 
BMI 28.0±6.2 29.4±6.0 29.9±4.3 29.1±5.8 27.3±5.8 32.1±7.4 
eGFR (ml/min/1.73M2) 107.1±15.3 79.6±18.1 93.4±12.2 N.A. 63.8 ± 19.4 81.6±25.6 
Creatinine (mg/dL) 0.8±0.1 1.0±0.3 0.8±0.2 1.0 ±0.8 0.9 ±0.3 -- 
Albumin (mg/dL) 4.3±0.4 4.3±0.3 4.5±0.2 3.2±0.8 3.6±0.4 3.6±0.3 
Calcium (mg/dL) 9.3±0.4 9.4±0.4 9.2±0.3 8.8±0.7 9.0±0.4 9.1±0.6 
Corrected Calcium 
(mg/dL) 
9.1±0.3 9.1±0.4 8.8±0.3 9.4±0.6 9.4±0.2 n.a. 
iPTH (pg/mL)^ 42.2 ±20.0 44.1±24.7 52.8±20.8 38.8 ±35.3 48.1±25.5 21.8 ±18.0 
Free 25(OH)D (pg/mL) 
•~*
◊
 
4.3±1.9◊  4.5±1.8◊  5.5±1.7◊  7.1 ±3.0◊  9.5±3.8◊  4.0 ±1.1◊  
Total 25 (OH)D 
(ng/mL) #~*∞ 
21.9±9.9~∞ 22.5±9.1~∞ 24.4±8.7∞  18.7±10.6∞  34.9±12.8∞  26.7 ±10.0∞  
Per Cent Free 25(OH) 
D*∇ 
0.020±.006 ∇ 0.021±.008∇ .023±.006∇ .040±.020∇ .028±.006∇ .016±.006∇ 
D Binding Protein 
(mcg/mL) `*∨ 
293 ±51.1∨ (n=159) 294.1±36.5∨ (n=495) 299.2±41.4∨ 
(n=476) 
175.5±64.7∨ 
(n=58) 
264.2±38∨ 
(n=78) 
529±49.5∨ 
(n=20) 
Data are mean ± S.D. unless otherwise noted. ^ measured in clinical laboratories by multiple methods.  • Assays 
performed at Future Diagnostics, BV except prediabetics had assays using same method at the Investigator site. # 
Assays were by LC MS/MS except for 69 (of 90) cirrhotics by Diasorin (LIAISON) that were corrected by a 
calibration factor provided by the Manufacturer. ~ multiple samples of total and free 25(OH D from some 
individuals from dose titrations studies.  ` D Binding Protein Measurements by radial immunodiffusion assay 
(Leuven)—with the exception of pregnant women determined by R&D assay (in italics).* Significant effect of 
clinical group (ANOVA, p<.0001), ◊ post hoc between group comparisons were significant at p<.0033 for all but 
normals vs. pregnant or outpatients, or for pregnant vs. outpatients. ∞ post hoc between group comparisons were 
significant at p<.0033 for all but normals compared to outpatients, or pregnant or cirrhotic, or for pregnant compared 
to outpatients or prediabetics.  ∇ Post hoc between group comparisons were significant at p<.0033 for all but normals 
compared to pregnant or outpatients, or for pregnant vs. outpatients.  ∨ Post Hoc between group comparisons were 
significant at p<.0033 for all but normals compared to outpatients or prediabetics, or for prediabetics compared to 
outpatients.  
Table 2. Free, Total, and Per cent Free 25(OH)D and D Binding Protein by DBP Haplotype 
DBP 
Haplotype                        
Frequency (%)*  Free 25(OH)D 
(pg/mL)** 
Total 25(OH)D 
(ng/mL)** 
Per Cent Free 
25(OH)D** 
DBP (RID) 
(mcg/mL)** 
 Whites 
(n=860) 
Blacks 
(n=98) 
Other 
(n=1) 
    
1s/1s 31.9 1 0 5.1±1.8 25.6 ± 10.0 .021±.006 308.6 ±40 n=209 
1s/2 29 1 100 5.1±2.1 23.1 ±8.4 .023±.007 287.9 ±36.2  
n=182 
1s/1f 22.4 27 0 5.4±2.0 24.2 ±9.0 .023±.007 304.5 ±39.7 n=189 
2/2 5.5 0 0 4.1 ±2.0 17.8 ±7.3 .023±.007 260.4 ±25.1 n=24 
1f/2 8.3 18 0 4.7±1.8 19.6 ±7.7 .026±.010 289.3 ±34.1 n=73 
1f/1f 3 51 0 4.4±1.6 18.2± 8.2 .026±.008 300.1 ±43.5 n=73 
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*Significant differences in frequencies of haplotypes between the races for all haplotypes except for Gc1s/1f were 
detected.  
**Statistically significant effects of DBP haplotype were detected for Total, free and per cent free 25 (OH)D 
concentrations and DBP (ANOVA, p<.0001; see Fig 2 and text for individual between haplotype post hoc 
comparisons.)  
Table 3. Linear mixed model analysis of Relationship between Free and Total 25(OH)D  
Model: Linear mixed effects regression Coefficient S.E. t value p value 
Model Selected Covariates     
a (Intercept) 1.291 .0781 16.521 <.000001 
b (slope) 0.186 .0085 22.024 <.000001 
Selected Covariates     
 Clinical Class                                                               
Community –dwelling/Outpatients -.0094 .0046 -2.026 <.05 
Prediabetics 0.0245 .0049 5.010 <.000001 
Cirrhotics 0.1577 .0080 19.763 <.000001 
Nursing Home Residents 0.0873 .0064 13.585 <.000001 
Pregnant -.0450 .0126 -0.357 <.0001 
 BMI -.0013 .0003 -4.926 <.000001 
The fixed effect model takes the form Free = a + (b +c COV)Total, where a is the intercept, b is the slope of the 
relationship Free vs Total 25(OH)D, and c is a vector of parameters quantifying the relationship of the slope with 
covariates. Variables tested but not selected included eGFR and race. Sex was not tested in this model.     T and p 
values represent comparisons to the baseline slope of the model (normals). 
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